<DOC>
	<DOCNO>NCT00880477</DOCNO>
	<brief_summary>This study assess immunogenicity , safety reactogenicity GSK Biological 's DTPa-HBV-IPV/ Hib vaccine compare GSK 's DTPa-IPV/Hib vaccine co-administered HBV accord three-dose immunisation course booster dose infant bear hepatitis B antigen seronegative mother previously prim birth dose GSK 's HBV vaccine .</brief_summary>
	<brief_title>Immunogenicity Safety Primary Booster Vaccination With DTPa-HBV-IPV/Hib Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Pentetic Acid</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<criteria>Inclusion criterion enrolment birth Written inform consent obtain parent guardian subject . A male female infant bear normal gestation period ( 36 42 week ) . Born mother seronegative HBsAg . Free obvious health problem establish clinical examination enter study . Inclusion criterion administration combine vaccine regimen Between , include , 6 8 week age time first dose threedose course vaccination . Free obvious health problem establish medical history clinical examination enter phase study . Inclusion criterion administration booster dose Between , include , 15 18 month age time booster vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Completion threedose primary vaccination course . Exclusion criterion enrolment birth A family history congenital hereditary immunodeficiency . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus infection . Major congenital defect ( ) . Exclusion criterion administration combine vaccine regimen Use investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration Immunosuppressants immunemodifying drug since birth . Any chronic drug therapy continue study period . Planned administration/ administration vaccine except Bacille CalmetteGu√©rin vaccine period start 30 day dose vaccine end 30 day . Previous vaccination diphtheria , tetanus , pertussis Haemophilus influenzae type b disease . History , intercurrent , diphtheria , tetanus , pertussis , hepatitis B and/or Haemophilus influenzae type b disease . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus infection . History allergic disease reaction likely exacerbate component vaccine . Serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment . Administration immunoglobulins and/or blood product since birth plan administration study period . Exclusion criterion administration booster dose Use investigational nonregistered drug vaccine study vaccine within 30 day precede booster dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month vaccination . Previous booster vaccination diphtheria , tetanus , pertussis , hepatitis B , polio and/or Haemophilus influenzae type b . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus infection . History allergic disease reaction likely exacerbate component vaccine . Acute disease time enrolment . History neurologic disorder seizure . Administration immunoglobulins and/or blood product within three month precede booster dose study vaccine plan administration study period . Hypersensitivity reaction due vaccine primary course Encephalopathy within 7 day previous vaccination DTP vaccine</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>8 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>